AYTU BIOPHARMA, INC Quarterly Net Income (Loss) Attributable to Parent in USD from Q4 2010 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Aytu Biopharma, Inc quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q4 2010 to Q4 2024.
  • Aytu Biopharma, Inc Net Income (Loss) Attributable to Parent for the quarter ending December 31, 2024 was $788K.
  • Aytu Biopharma, Inc Net Income (Loss) Attributable to Parent for the twelve months ending December 31, 2024 was -$5.24M, a 70.9% increase year-over-year.
  • Aytu Biopharma, Inc annual Net Income (Loss) Attributable to Parent for 2024 was -$15.8M, a 7.08% increase from 2023.
  • Aytu Biopharma, Inc annual Net Income (Loss) Attributable to Parent for 2023 was -$17.1M, a 84.3% increase from 2022.
  • Aytu Biopharma, Inc annual Net Income (Loss) Attributable to Parent for 2022 was -$109M, a 86.6% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2024 -$5.24M $788K +$1.01M Oct 1, 2024 Dec 31, 2024 10-Q 2025-02-12
Q3 2024 -$6.25M $1.47M +$9.59M Jul 1, 2024 Sep 30, 2024 10-Q 2025-02-12
Q2 2024 -$15.8M -$4.62M -$2.16M -87.9% Apr 1, 2024 Jun 30, 2024 10-K 2024-09-26
Q1 2024 -$13.7M -$2.89M +$4.31M +59.9% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 -$18M -$220K +$6.47M +96.7% Oct 1, 2023 Dec 31, 2023 10-Q 2025-02-12
Q3 2023 -$24.5M -$8.12M -$7.42M -1058% Jul 1, 2023 Sep 30, 2023 10-Q 2025-02-12
Q2 2023 -$17.1M -$2.46M +$13.6M +84.7% Apr 1, 2023 Jun 30, 2023 10-K 2024-09-26
Q1 2023 -$30.7M -$7.2M +$46.1M +86.5% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 -$76.8M -$6.69M +$4.86M +42% Oct 1, 2022 Dec 31, 2022 10-Q 2024-05-15
Q3 2022 -$81.6M -$701K +$27.2M +97.5% Jul 1, 2022 Sep 30, 2022 10-Q 2024-05-15
Q2 2022 -$109M -$16.1M +$2.91M +15.3% Apr 1, 2022 Jun 30, 2022 10-K 2023-10-12
Q1 2022 -$112M -$53.3M -$27.8M -109% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 -$83.9M -$11.5M -$2.02M -21.2% Oct 1, 2021 Dec 31, 2021 10-Q 2023-05-11
Q3 2021 -$81.8M -$27.9M -$23.5M -547% Jul 1, 2021 Sep 30, 2021 10-Q 2023-05-11
Q2 2021 -$58.3M -$19M -$15.9M -504% Apr 1, 2021 Jun 30, 2021 10-K 2022-09-27
Q1 2021 -$42.4M -$25.5M -$20.1M -377% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q4 2020 -$22.3M -$9.53M -$9.31M -4346% Oct 1, 2020 Dec 31, 2020 10-Q 2022-02-14
Q3 2020 -$13M -$4.31M +$623K +12.6% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 -$13.6M -$3.15M +$11.4M +78.4% Apr 1, 2020 Jun 30, 2020 10-K 2021-09-28
Q1 2020 -$25M -$5.33M -$836K -18.6% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-17
Q4 2019 -$24.2M -$214K +$4.44M +95.4% Oct 1, 2019 Dec 31, 2019 10-Q 2021-05-17
Q3 2019 -$28.6M -$4.93M -$1.48M -43% Jul 1, 2019 Sep 30, 2019 10-Q 2021-05-17
Q2 2019 -$27.1M -$14.5M -$15.1M -2754% Apr 1, 2019 Jun 30, 2019 10-K 2020-10-06
Q1 2019 -$12.1M -$4.5M -$1.68M -59.6% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-15
Q4 2018 -$10.4M -$4.66M -$985K -26.8% Oct 1, 2018 Dec 31, 2018 10-Q 2020-05-15
Q3 2018 -$9.39M -$3.45M +$799K +18.8% Jul 1, 2018 Sep 30, 2018 10-Q 2020-05-15
Q2 2018 -$10.2M $548K +$7.3M Apr 1, 2018 Jun 30, 2018 10-K 2019-09-26
Q1 2018 -$17.5M -$2.82M +$2.4M +46% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-14
Q4 2017 -$19.9M -$3.67M +$1.14M +23.8% Oct 1, 2017 Dec 31, 2017 10-Q 2019-05-14
Q3 2017 -$21M -$4.25M +$1.48M +25.8% Jul 1, 2017 Sep 30, 2017 10-Q 2019-05-14
Q2 2017 -$22.5M -$6.75M +$8.55M +55.9% Apr 1, 2017 Jun 30, 2017 10-K 2018-09-06
Q1 2017 -$31.1M -$5.22M +$2.06M +28.3% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-14
Q4 2016 -$33.1M -$4.82M -$1.48M -44.6% Oct 1, 2016 Dec 31, 2016 10-Q 2018-02-08
Q3 2016 -$31.6M -$5.72M -$3.45M -151% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-09
Q2 2016 -$28.2M -$15.3M -$13.1M -610% Apr 1, 2016 Jun 30, 2016 10-K 2017-08-31
Q1 2016 -$15M -$7.27M -$5.43M -295% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-11
Q4 2015 -$9.61M -$3.33M -$1.71M -106% Oct 1, 2015 Dec 31, 2015 10-Q 2017-02-09
Q3 2015 -$7.89M -$2.28M -$171K -8.13% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-07
Q2 2015 -$7.72M -$2.16M -$2.14M -18129% Apr 1, 2015 Jun 30, 2015 10-K 2016-09-01
Q1 2015 -$5.58M -$1.84M -$162K -9.63% Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-11
Q4 2014 -$5.42M -$1.62M -$1.6M -9718% Oct 1, 2014 Dec 31, 2014 10-Q 2016-02-11
Q3 2014 -$3.81M -$2.11M -$2.09M -19882% Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-06
Q2 2014 -$1.72M -$11.8K +$1.44K +10.9% Mar 1, 2014 May 31, 2014 10-Q 2014-07-10
Q1 2014 -$1.72M -$1.68M -$1.67M -12202% Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-19
Q4 2013 -$54K -$16.5K +$3.35K +16.9% Sep 1, 2013 Nov 30, 2013 10-Q 2015-01-12
Q3 2013 -$57.3K -$10.5K +$7.45K +41.4% Jun 1, 2013 Aug 31, 2013 10-K 2014-11-26
Q2 2013 -$64.8K -$13.3K -$1.33K -11.1% Mar 1, 2013 May 31, 2013 10-Q 2014-07-10
Q1 2013 -$63.4K -$13.7K -$3.58K -35.5% Dec 1, 2012 Feb 28, 2013 10-Q 2014-04-11
Q4 2012 -$59.9K -$19.9K -$192 -0.98% Sep 1, 2012 Nov 30, 2012 10-Q 2014-01-10
Q3 2012 -$59.7K -$18K +$53.5K +74.9% Jun 1, 2012 Aug 31, 2012 10-K 2014-11-26
Q2 2012 -$113K -$11.9K +$8.78K +42.4% Mar 1, 2012 May 31, 2012 10-Q 2012-06-26
Q1 2012 -$122K -$10.1K +$16.8K +62.4% Dec 1, 2011 Feb 29, 2012 10-Q 2012-04-12
Q4 2011 -$139K -$19.7K -$1.95K -11% Sep 1, 2011 Nov 30, 2011 10-Q 2013-01-14
Q3 2011 -$137K -$71.5K Jun 1, 2011 Aug 31, 2011 10-K 2014-11-26
Q2 2011 -$20.7K Mar 1, 2011 May 31, 2011 10-Q 2012-06-26
Q1 2011 -$26.8K Dec 1, 2010 Feb 28, 2011 10-Q 2012-04-12
Q4 2010 -$17.7K Sep 1, 2010 Nov 30, 2010 10-Q 2011-12-23
* An asterisk sign (*) next to the value indicates that the value is likely invalid.